AnaptysBio, Inc.
NASDAQ•ANAB
CEO: Mr. Daniel R. Faga
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-01-26
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Contact Information
10770 Wateridge Circle, Suite 210, San Diego, CA, 92121-5801, United States
858-362-6295
Market Cap
$1.72B
P/E (TTM)
-130.2
17.5
Dividend Yield
--
52W High
$63.47
52W Low
$15.32
52W Range
Rank60Top 89.2%
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$108.25M+0.00%
4-Quarter Trend
EPS
$1.79+0.00%
4-Quarter Trend
FCF
$98.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Collaboration Revenue Jumps Total collaboration revenue reached $234.6M in 2025, up $143.3M driven by Jemperli milestones and royalties.
Significant Net Loss Improvement Net loss narrowed substantially to $(13.2M) in 2025 from $(145.2M) in 2024 due to high collaboration revenue.
Rosnilimab Phase 2b Success Rosnilimab Phase 2b trial met primary endpoint for RA; demonstrated statistical significance on ACR20 across all doses.
Cash Position Significantly Increased Cash and equivalents totaled $238.2M by year-end 2025, increasing $115.1M from prior year balances.
Risk Factors
Product Development Failure Risk Product candidates may fail clinical trials or face delays; historical failure rates are high, impacting commercial viability.
Sustained Operating Losses Risk Company has limited operating revenue, history of losses, and $772.6M accumulated deficit; profitability remains uncertain.
Collaboration Termination Exposure Business heavily dependent on GSK and Vanda collaborations; termination or disputes could severely affect revenue streams.
Biologics Manufacturing Complexity Manufacturing biologics is complex; third-party manufacturer difficulties could delay clinical supply or halt marketing approval efforts.
Outlook
Planned Corporate Separation Intends to complete separation into Royalty Management Co and Biopharma Co by Q2 2026 to focus operations.
Advancing Wholly Owned Pipeline Focus on advancing rosnilimab, ANB033, and ANB101 through clinical stages toward potential commercialization.
Royalty Value Protection Strategy Royalty Management Co will focus on protecting and returning value from GSK Jemperli royalties and Vanda milestones.
Peer Comparison
Revenue (TTM)
$234.60M
$185.74M
$175.11M
Gross Margin (Latest Quarter)
199.8%
100.0%
97.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| DNTH | $3.15B | -20.2 | -38.8% | 0.3% |
| TNGX | $1.92B | -18.9 | -50.3% | 8.4% |
| ANAB | $1.72B | -130.2 | 1813.8% | 79.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
57.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Deep Research
Next earnings:May 4, 2026
EPS:-$0.72
|Revenue:$23.07M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data